View Cancer Clinical Trials

Details

Title Multicenter Phase 1 b/2 Study of Tivozanib in Patients with Advanced Inoperable Hepatocellular Carcinoma

IRB RPCI1213

CC 011419C

Hospital Main Campus

Phase Phase 1, Phase 2

Disease Liver

Drug Tivozanib

Description

Primary Objective:

• The primary endpoint of the study is PFS at 24 weeks in patients with advanced HCC. Patients who remain alive without evidence of disease progression (per RECIST) for at least 24 weeks after enrollment will be considered PFS responders.

Secondary Objectives:

• To determine the safety of tivozanib in HCC.
• To determine the OS and clinical benefit rate (CR, PR and SD) by RECIST.
• To determine the steady state PK and soluble VEGFR-2 baseline/ change with tivozanib and use modeling to correlate exposure with biomarker change and the primary outcome measure of PFS.
• To determine the change in viral load (HBV and HCV) during therapy in patients with HBV or HCV associated HCC.
• To determine the change in tumor marker (alfa fetoprotein) with tivozanib therapy is in the effect of tivozanib on several tumor-associated immune response markers.

Inclusion Criteria

1. Advanced staged HCC (unresectable and not amenable to local or regional therapy; or metastatic HCC). The diagnosis of HCC should be based on at least one of the following:
   • MRI or CT consistent with liver cirrhosis AND at least one solid liver lesion measuring ≥ 2 cm, with characteristics arterial enhancement and venous washout regardless of AFP levels.
   • AFP ≥ 400 ng/mL AND evidence of at least one solid liver lesion ≥ 2 cm regardless of specific imaging characteristics on CT or MRI.
   • Histological/cytology biopsy confirming HCC.
2. Patients must have measurable disease per RECIST 1.1 criteria defined as at least one lesion that can be accurately measured in at least one dimension, and that has not been the target of local or regional therapy including transarterial chemoembolization, intra-arterial chemotherapy, ethanol or radiofrequency ablation.
3. Age ≥ 18 years.
4. Life expectancy of greater than 3 months.
5. Patients must have organ and marrow function as defined below:
   • Child-Pugh liver function Class A. (Appendix G)
   • AST ≤ 5 x Institutional upper limits of normal (ULN)
   • Total bilirubin ≤ 3 mg/dL
   • INR ≤ 2.0
   • Serum albumin > 2.8 g/dL
   • Creatinine ≤ 1.5 x Institutional ULN
   • ANC > 1200/mm³
   • Platelets ≥ 60,000/mm³
   • Hgb ≥ 8.5 g/dL

   NOTE: The lower absolute neutrophil count (ANC) and platelet cut-offs are designed to accommodate the large number of patients with HCC who have portal hypertension and splenic sequestration. Given the adverse profile of tivozanib these reduced cut-offs are thought to be safe.

6. Patients must not have any evidence of bleeding diathesis or active gastrointestinal bleeding.
7. Patients must not be known to be HIV positive; drug-drug interaction with study medication and HIV medications is not well-characterized and could lead to unwanted side effects.
8. Patients must not have other uncontrolled intercurrent illnesses (excluding HBV or HCV). This includes (but is not limited to) ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
9. Sexually active fertile patients (male and female), and their partners, must agree to use medically accepted methods of contraception during the course of the study and for 3 months after the last dose of the study drug.
10. Female patients of childbearing potential must have a negative pregnancy test at screening.
11. Have an ECOG Performance Status of ≤ 2. Refer to Appendix B.
12. Subject or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure.

Exclusion Criteria

1. Patients who have had prior anti-angiogenic therapy, including but not limited to sorafenib, brivanib, bevacizumab, or sunitinib.
2. Patients who have had any prior line of systemic therapy including cytotoxic agents or molecularly targeted agents for advanced/unresectable disease. Any number of prior regional therapies with transarterial chemoembolization (TACE), brachytherapy with Yttrium-90 microsphere, intra-arterial chemotherapy, surgery, or ablative therapy are allowed.
3. Prior liver transplantation and on immunosuppression; drug-drug interaction with study medication and immunosuppression is not well characterized and could lead to unwanted side effects.
4. Known symptomatic or uncontrolled brain metastases or epidural disease.
5. Patient has a corrected QT interval (QTcF) > 500 ms at screening.
6. The patient is unable to swallow pills or diagnosed with a gastrointestinal disorder that are likely to interfere with the absorption of the study drug or with the patient's ability to take regular oral medication.
7. The patient is pregnant or breastfeeding.
8. Patients with second primary cancer (except adequately treated nonmelanoma skin cancer, curatively treated in-situ carcinoma of the cervix or superficial bladder cancer, or other solid tumors including lymphoma without bone marrow involvement curatively treated with no evidence of disease for ≥ 5 years).
9. The patient has a previously-identified allergy or hypersensitivity to components of the study treatment formulation.
10. Patients receiving any medications or substances that are strong inducers of CYP3A4 are ineligible. Moderate and mild inducers of CYP3A4 should be used with caution, as they may reduce the efficacy of Tivozanib.
11. Urine protein: creatinine ratio > 1 see (Appendix- H)